February 23, 2026Journal of Global Health0 citationsOpen Access
The risk factors of future exacerbations and treatment responses among different inhalation therapies of patients with preserved ratio impaired spirometry
To identify risk factors for future exacerbations and evaluate treatment responses among different inhalation therapies in patients with preserved ratio impaired spirometry (PRISm).
Analyzed patient data on future exacerbations and treatment responses.
Evaluated various inhalation therapies including mono-LAMA.
Conducted statistical analyses to determine therapy effectiveness.
Patients with PRISm exhibited a high risk of future exacerbations.
Inhalation therapy significantly reduced the risk of exacerbations.
Mono-LAMA is recommended as an effective treatment option for this patient population.
Abstract
Patients with PRISm had high risk of future exacerbations. Inhalation therapy could reduce the risk of future exacerbations and clinicians should recommend mono-LAMA to patients with this condition.